Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology. Impressions of the 25th Annual Meeting of the Chinese Society of Anaesthesiology - CSA2017 - 中华医学会第25 次全国麻醉学术年会
The CICS Annual Conference on Immuno Oncology is offering the most significant advances in the world of oncology. The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.
Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.
ESMO 2016 ipilimumab data is largely focussed on melanoma. Of the three Late Breaking Abstracts (LBA), two will discuss the use of ipilimumab in melanoma. The third LBA will discuss the use of ipilimumab in squamous cell head and neck cancer (SCCHN / HNSCC).
Late breaking abstracts at ESMO 2016 with pembrolizumab are largely in lung cancer. Data includes the phase III Keynote-010, the Keynote-024 study, and a study combining ramucirumab with pembrolizumab in NSCLC will be presented. Furthermore, late breaking abstracts will include data of pembrolizumab in urothelial cancer, the KEYNOTE-052 study.
Avelumab and durvalumab both are PD-L1 targeted antibodies, similar to atezolizumab (Tecentriq™), which was recently approved by the US FDA. Tremelimumab is a CTLA-4 inhibitor, similar to ipilimumab. It is a drug with a long history and also known as CP-675,206 and ticilimumab. The drug has been extensively investigated with mixed results.
ESMO 2016 atezolizumab data is focussed on lung cancer, melanoma, and urothelial cancer. Data includes cohort 1 of the Phase II IMvigor 210 Study in first-line metastatic Urothelial Cancer (mUC). The latest U.S. FDA approved indication for atezolizumab was Metastatic Urothelial Cancer in May 2016.
ESMO 2016 nivolumab data in Late Breaking Abstracts is focused on two studies in non-small cell lung cancer (NSCLC; CheckMate 026 and a neoadjuvant study), one presentation in combination with ipilimumab in stage 3 palpable melanoma (OpACIN trial), and finally a presentation in metastatic urothelial carcinoma (mUC; CheckMate-275 trial).